Drug Development

Kleiner Perkins is lining up a new $400M tech fund

Legendary Silicon Valley venture group Kleiner Perkins Caufield & Byers — a player in the biotech arena — has outlined plans to raise $400 million for a new fund in a filing yesterday with the SEC.

That number may well just be a place holder for the final figure. CNBC reported a few weeks ago that Kleiner Perkins was raising two funds for a total of about $1.3 billion, quoting sources. About $800 million of that was being reserved for more mature companies while the rest would be startup oriented.

Beth Seidenberg

Beth Seidenberg

The high profile Beth Seidenberg, a former R&D exec who joined KPCB after a stint as CMO at Amgen, is listed in the filing, which was dispatched on Thursday. Her role as a VC player has put her on the boards of 3-V Biosciences, ARMO Biosciences, Breathe Technologies, FLX, Hixme, Kinsa, Mango Health, Practice Fusion, Progyny and True North; as well as three publicly traded companies: Atara Bio (ATRA), Epizyme (EPZM) and Tesaro (TSRO).

We’d ask her for a comment, but the venture firm is in a quiet period now, so we’ll save that for later.

Get Endpoints News in your inbox

Newsletters for those who discover, develop, and market drugs. Enjoy the news with the story intact — entire articles in your inbox, no clicks required. Join 12,000+ biopharma pros who read Endpoints News every day. Free subscription.


Subscribe to Endpoints

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy